Wall Street urged Pfizer to lower its COVID revenue estimates. The company did — but it's still betting on higher demand for its vaccine and antiviral by 2025. Read More...
Pfizer PFE put out its yearly sales guidance for Comirnaty, the COVID-19 vaccine it developed with BioNTech BNTX, saying it expects $13.5 billion in revenue this year. The shot brought in $37.8 billion in 2022.
The drugmaker also set out revenue expectations for its COVID antiviral, Paxlovid, to $8.0 billion for the year. That’s lower than the FactSet consensus of $10.4 billion for 2023 and a 57% drop in year-over-year revenue compared with the $18.9 billion that the drug generated for Pfizer in 2022.
The…
